Shah, Aishwarya
Gerber, Naamit Kurshan
Article History
Accepted: 22 June 2023
First Online: 19 July 2023
Declarations
:
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: Dr. Gerber reports grants from Prelude Dx, outside the submitted work. We discuss this company’s assay for DCIS in this review article.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: This was an abstract that reported that patients in the low-risk group (as per biosignature that combined DS with RRt) did not have a benefit of BCS and endocrine therapy but patients in the elevated-risk and residual-risk group did have a lower 10-year IBR than BCS alone.